Phase 4 N=48 Selegiline to Zelapar Switch Study in Parkinson Disease Patients
Parkinson's Disease
Primary: Clinical Global Impression Scale — 21; 27 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=417 A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study
Glaucoma and Ocular Hypertension
Primary: Intraocular Pressure (IOP) at Week 1 — 19.4; 19.7; 18.5; 18.9 mmHg
Phase 3 N=231 Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain
Osteoarthritis, Knee
Primary: Change From Baseline in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score — -44.3; -37.5; -36.1 score on a scale — p=0.0406
Phase 2 N=72 A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder
Cannabis Use Disorder
Primary: Marijuana Craving Questionnaire-Short Form Score as a Measure of Behavioral Craving — 45.8; 45.2; 27.7; 22.6 score on a scale
Phase 3 N=144 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Dim Light Vision Disturbances
Primary: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye — 9; 2 Participants
N/A N=39 Gestational Weight and Incentive Research Study
Gestational Weight Gain
Primary: Intervention Satisfaction Observed From Follow-up Survey — 5; 4.25; 4.25; 5 units on a scale
N/A N=15 C-Pulse® System European Multicenter Study
Heart Failure
Primary: Survival and Study Completion — 11; 4 Participants
N/A N=32 Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique
Osteoarthritis
Primary: OR Total Time — 93.00; 92.72 minutes
Phase 3 N=861 A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
COVID-19 Prevention
Primary: Groups 1 and 2: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibodies Against Each of the Four Influenza Vaccine Strains 28 Days After the…
Phase 3 N=172 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants Able to Self-administer Safe and Effective Injections Using the Bimekizumab-safety Syringe (SS)-1mL or the Bimekizumab-auto-injector (AI)-1mL…
Phase 3 N=1,610 A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
Meningococcal Vaccine
Primary: Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary…
N/A N=63,012 Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities
Diabetes Mellitus
Primary: Percent of Participants Using Mail Order Pharmacy (MOP) After Intervention — 10.6; 9.3 percentage of participants — p=<0.001
Phase 2 N=6 PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
Cancer
Primary: Microvascular Damage/Endothelial Dysfunction — 0 Participants
N/A N=42 Atomoxetine PBPK-PD Clinical Study
ADHD
Primary: Number of Participants Classified as Responders and Non-responders to Intervention — 14; 15 Participants
N/A N=628 REseArCH INteGration in Women, Infants, and Children
Body Weight Changes
Primary: Receptiveness to Weight Management Interventions in the WIC Program — 126; 184; 6; 190 Participants